Correction: Comparative Effectiveness and Safety of Medications for Type 2 Diabetes
Authors: Wendy L. Bennett, Eric B. Bass, Shari Bolen
Journal: Annals of Internal Medicine (2011)

Corrections5 July 2011Correction: Comparative Effectiveness and Safety of Medications for Type 2 DiabetesFREEWendy L. Bennett, MD, MPH, Eric B. Bass, MD, MPH, and Shari Bolen, MD, MPHWendy L. Bennett, MD, MPHFrom The Johns Hopkins University School of Medicine, Baltimore, MD 21205, and Case Western Reserve University School of Medicine, Cleveland, OH 44106.Search for more papers by this author, Eric B. Bass, MD, MPHFrom The Johns Hopkins University School of Medicine, Baltimore, MD 21205, and Case Western Reserve University School of Medicine, Cleveland, OH 44106.Search for more papers by this author, and Shari Bolen, MD, MPHFrom The Johns Hopkins University School of Medicine, Baltimore, MD 21205, and Case Western Reserve University School of Medicine, Cleveland, OH 44106.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-155-1-201107050-00016 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We would like to correct a pooled odds ratio published in our systematic review on the comparative effectiveness and safety of medications for type 2 diabetes mellitus (1). The article states, “Seven short-duration RCTs [randomized, controlled trials] reported a lower risk for fatal and nonfatal ischemic heart disease with metformin than with the combination of metformin and rosiglitazone (pooled odds ratio, 0.43 [95% CI, 0.17 to 1.10]), but event rates were low and the confidence bounds were wide and overlapped 1.0.” However, we identified an error in data abstraction from Gómez-Perez and colleagues' study (2) and recalculated the pooled odds ratio for this comparison.We used the denominator of 76 patients in the metformin and rosiglitazone group; the correct denominator is 77 patients. This has been corrected in the online version of Appendix Figure 3.Furthermore, the correct total pooled odds ratio and 95% CI are 0.46 (0.18 to 1.19), not 0.43 (0.17 to 1.10). This has been corrected in the revised Figure shown here.Figure. Odds of fatal and nonfatal ischemic heart disease with metformin monotherapy and metformin plus rosiglitazone.Error bars represent 95% CIs. Met = metformin; Rosi = rosiglitazone. Download figure Download PowerPoint Wendy L. Bennett, MD, MPHEric B. Bass, MD, MPHThe Johns Hopkins University School of MedicineBaltimore, MD 21205Shari Bolen, MD, MPHCase Western Reserve University School of MedicineCleveland, OH 44106References1. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-13. [PMID: 21403054] LinkGoogle Scholar2. Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18:127-34. [PMID: 11994904] CrossrefMedlineGoogle Scholar3. Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie MG, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabet Med. 2006;23:1069-78. [PMID: 16978370] CrossrefMedlineGoogle Scholar4. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005;27:1548-61. [PMID: 16330291] CrossrefMedlineGoogle Scholar5. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5:163-70. [PMID: 12681023] CrossrefMedlineGoogle Scholar6. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695-702. [PMID: 10755495] CrossrefMedlineGoogle Scholar7. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005;21:2029-35. [PMID: 16368054] CrossrefMedlineGoogle Scholar8. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8:650-60. [PMID: 17026489] CrossrefMedlineGoogle Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Wendy L. Bennett, MD, MPH; Eric B. Bass, MD, MPH; Shari Bolen, MD, MPHAffiliations: From The Johns Hopkins University School of Medicine, Baltimore, MD 21205, and Case Western Reserve University School of Medicine, Cleveland, OH 44106.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2867. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations Wendy L. Bennett , Nisa M. Maruthur , Sonal Singh , Jodi B. Segal , Lisa M. Wilson , Ranee Chatterjee , Spyridon S. Marinopoulos , Milo A. Puhan , Padmini Ranasinghe , Lauren Block , Wanda K. Nicholson , Susan Hutfless , Eric B. Bass , and Shari Bolen Metrics Cited byProbiotic strains and mechanistic insights for the treatment of type 2 diabetesCYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects 5 July 2011Volume 155, Issue 1Page: 67-68KeywordsCardiovascular therapyConflicts of interestDisclosureDrug safetyOdds ratioRisk managementSystematic reviewsType 2 diabetes ePublished: 5 July 2011 Issue Published: 5 July 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...